← Leaderboards
Chiara Federici
Biochip Labs, Inc.
$2,197,970
Attributed
$4,395,940
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,395,940 · 3
By mechanism
R42$4,395,940 · 3
Top collaborators
- Umut A. Gurkan9 shared
Others in their field
Other Emerging Leaders on “Blood Vessels”
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Michael P Harms · Washington University$13,645,932
- Barbara Halina Braffett · George Washington University$13,172,222
- Alberto Rafael Ramos · University Of Miami School Of Medicine$11,170,423
Research focus
Blood VesselsPharmaceutical PreparationsTranslatingSickle Cell AnemiaMicrofluidicsAcute Chest SyndromeSmall Business Technology Transfer ResearchMediatingQuality ControlValidationComorbidityErythrocytesStrokeCell AdhesionPharmacologic SubstanceStandardizationTargeted AgentMortalityHematological DiseaseMorbidity - Disease RatePainPropertyDesignInherited
Grant awards (9)
Manufacturing and Analytical Validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for Commercial Viability$312,371
R42 · FY2025 · HL · contact PI
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$865,375
R42 · FY2024 · HL · contact PI
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability (Administrative Supplement)$70,840
R42 · FY2024 · HL · contact PI
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$865,376
R42 · FY2023 · HL · contact PI
Endothelialized microfluidic assays for emerging therapies in sickle cell disease$842,828
R42 · FY2023 · HL · contact PI
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$70,840
R42 · FY2023 · HL · contact PI
Endothelialized microfluidic assays for emerging therapies in sickle cell disease$852,121
R42 · FY2022 · HL · contact PI
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$259,611
R42 · FY2022 · HL · contact PI
Endothelialized microfluidic assays for emerging therapies in sickle cell disease$256,578
R42 · FY2021 · HL · contact PI